louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01620034: Lung Stereotactic Body Radiotherapy (SBRT) Delivered Over 4 Days Versus 11 Days
Official title: A Randomized Study of Stereotactic Body Radiotherapy (SBRT) for Lung Tumours Delivered Over 4 Days Versus 11 Days
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripherally Located Stage I Lung Cancer
Peripherally Located Solitary Lung Metastasis
Lead sponsor: Sunnybrook Health Sciences Centre
Sponsor class: OTHER
First posted: 2012-06-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Stereotactic Body Radiotherapy (SBRT) has emerged as a new treatment option for peripherally located lung tumours, offering very high rates of tumour eradication, with minimal side effects. Even though this treatment option is being adopted in more and more cancer centres, there is still no consensus about the optimal schedule for the radiation treatment. Generally speaking, most lung SBRT schedules involve delivering 3-4 days of radiation. At the Sunnybrook Odette Cancer Centre, the lung SBRT policy is to deliver 4 days of radiation over 11 days (each treatment given once very 3rd day). However, some centres deliver the same treatment over 4 days in a row (each treatment given once daily over 4 days). There is no evidence from the published literature to suggest that there is any difference in side effects between delivering the SBRT over 4 days versus 11 days. To confirm this, the investigators propose to conduct a comparative (randomized) study to compare these 2 approaches.


Eligibility criteria: Inclusion Criteria:

* Pathologic diagnosis of malignancy in the lung (either NSCLC or metastasis)
* If pathologic diagnosis is not available, there must be evidence of FDG uptake on PET-CT suggestive of malignancy and/or evidence of tumour growth over serial CT scans
* Clinical stage I lung cancer or solitary lung metastasis located in the periphery away from central mediastinal structures and \<=5cm in size
* Patient deemed suitable for lung SBRT (reasonable performance status, acceptable pulmonary function) by the attending Radiation Oncologist

Primary outcomes:
measure: Rate of grade 2 or higher acute toxicity
timeFrame: Within 4 months after completion of therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Sunnybrook Odette Cancer Centre
state: Ontario
Study officials:
affiliation: Toronto Sunnybrook Regional Cancer Centre
name: Patrick Cheung, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01731834: Pain and Stress Assessment in Children
Official title: Pain and Stress Assessment in Children Undergoing Respiratory Physical Therapy Techniques
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Acute Respiratory Infections
Keywords: Pain
Stress
Physiotherapy
Children
Lead sponsor: Federal University of Uberlandia
Sponsor class: OTHER
First posted: 2012-11-22
Enrollment: 20
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: There may be pain and / or stress with vibrocompression. There may be pain and / or stress with the aspiration of secretions.

Detailed description: Randomization to 10 children and 10 vibrocompression for aspiration of secretion.

Fill in the evaluation form. Monitoring Heart Rate and Peripheral O2 Saturation (rest, during and after the technique performed).

Photographic Record (rest, during and after the technique performed). Saliva Collection (rest, 5, 20 and 40 minutes after running technics). Data analysis.

Eligibility criteria: Inclusion Criteria:

* Indication of Respiratory Therapy

Fasting for one hour before the moment of collection

Term of Free and Informed Consent Form (ICF) signed by parents or legal guardians

Exclusion Criteria:

* Children in postoperative period acute

Presence of thoracic drain or mediastinal

Children using drugs to sedative or analgesic purpose of deep sedation

Primary outcomes:
measure: Assess whether there is pain in children when performed randomized technique
timeFrame: two years
Secondary outcomes:
measure: Assess whether there is stress in children during the technical run
timeFrame: two years
Other outcomes:
measure: Correlate the pain and the stress generated.
timeFrame: two yars
Locations:
city: Uberlândia
country: Brazil
facility: FUUberlândia
state: Minas Gerais
Study officials:
affiliation: FUUberlândia
name: Maria Biasi, Third
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05525234: A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
Official title: A Prospective, Randomized, Double-blind, Placebo-controlled Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Haemodialysis
Uremic Pruritus
Thalidomide
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2022-09-01
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective, randomized, placebo-controlled
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.

Detailed description: A prospective, randomized, double-blind, placebo-controlled study was conducted to explore the efficacy and safety of thalidomide in the treatment of refractory urmia pruritus.

Eligibility criteria: Inclusion Criteria:

* Maintenance hemodialysis patients (≥3 month), 3 times/week, 4 hours/session
* spKT/V≥1.2
* The diagnosis was refractory urmia pruritus and pruritus score ≥8 score
* Patients with sleep disorders need to stop sleeping pills
* Be able to complete the form by yourself or with the help of others
* Informed consent

Exclusion Criteria:

* Participants in other clinical trials within 1 month
* People with thalidomide allergy
* Accompanied by severe calcium and phosphorus metabolism disorder (serum calcium≥3.0mmol/L or Serum phosphorus≥2.8mmol/L or Serum iPTH≥800pg/mL)
* Patients with other medical conditions that cause itchy skin
* With severe systemic infection, severe anemia and other serious complications
* Patients with peripheral neuropathy
* Other serious systemic diseases include systemic lupus erythematosus, multiple myeloma, thrombotic microangiopathy, and extensive metastasis of malignant tumors
* Patients with a history of thromboembolism were excluded from PICC-induced thrombosis
* Pregnant woman

Primary outcomes:
measure: Pruritus score
timeFrame: 12 weeks
Secondary outcomes:
measure: Efficacy index and response rate
timeFrame: 12 weeks
measure: Pittsburgh sleep quality score
timeFrame: 12 weeks
Other outcomes:
measure: Security Index
timeFrame: 12 weeks
Locations:
Study officials:
affiliation: Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University
name: Renhua Lu, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06736834: Sensory Evaluation of Chinese Specialty Foods
Official title: Sensory Evaluation of Chinese Specialty Foods
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dietary Preferences
Sensory Evaluation
Healthy Individuals
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2024-12-17
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This project aims at college student consumers, recruiting a certain number of college student volunteers as sensory evaluators, and requiring them to evaluate samples of Babao Congee and deep-fried dough sticks.

Detailed description: The specific evaluation methods are as follows: the samples are randomly numbered and distributed to college student volunteers. Scale method is used to quantify the appearance score, texture score and taste score of Babao Congee and deep-fried dough sticks. Basic information, general physical conditions and sensory characteristics of Babao Congee and deep-fried dough sticks are collected through questionnaires or interviews.

Eligibility criteria: Inclusion Criteria:

* University students at school

Exclusion Criteria:

* Smoking (≥1 cigarette/week);
* heavy alcohol consumption (\>224 g/week for men and \>168 g/week for women);

Primary outcomes:
measure: preference
timeFrame: Each sensory evaluation should be conducted within 2 hours, and for different batches of personnel, the overall time should be completed within one month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04335734: Influence of Wrap Fixation Technique on the Results of Fundoplication
Official title: Influence of Wrap Fixation Technique on the Results of Fundoplication
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastro Oesophageal Reflux Disease
Keywords: Gastro Oesophageal Reflux Disease, Nissen Fundoplication
Lead sponsor: Odessa National Medical University
Sponsor class: OTHER
First posted: 2020-04-06
Enrollment: 138
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients who underwent anti-reflux surgery were divided into two groups. In the I group Nissen fundoplication was supplemented with suturing wrap to the crura or the body of stomach using two non-absorbable stitches on each side. Control group included patients who underwent classic Nissen fundoplication without wrap fixation. All patients were assessed before and after surgery using validated symptoms and quality of life (GERD-HRQL) questionnaires, 24-h impedance-pH monitoring and barium-swallow.


Eligibility criteria: Inclusion Criteria:

* Age: 20 - 80 years;
* Gastroesophageal reflux disease as evidence by gastroscopy and pH-monitoring;
* HH type I, II

Exclusion Criteria:

* Age \< 20 years and \> 80 years;
* Unable to undergo laparoscopic fundoplication due to: severe comorbidities (ASA III and more), previous major surgery with severe adhesions, etc.;
* HH type III, IV;
* BMI \< 16 and \> 45 kg/m²;
* Pregnancy (in females);
* Oesophageal motility disorders;
* Oesophageal peptic strictures;
* Oesophageal diverticula, other types (i.e. non-reflux) of chronic esophagitis, connective tissue disorders (e.g. scleroderma);
* History of oesophageal/gastric/duodenal surgery including vagotomy;
* Relapsing course of ulcer disease/hyperacid gastritis including complicated by delayed gastric/duodenal emptying

Primary outcomes:
measure: Recurrence rate of hiatal hernia
timeFrame: 60 months
measure: Slipped wrap
timeFrame: 60 months
Secondary outcomes:
measure: Quality of life and satisfaction
timeFrame: 60 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00000234: Alternate Day Buprenorphine Administration, Phase XI - 16
Official title: Alternate Day Buprenorphine Administration, Phase XI
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Lead sponsor: University of Vermont
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 25
Maximum age (years): 51
Standard ages: ADULT
Accepts healthy volunteers: no
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Drug use
measure: Opioid withdrawal
measure: Opioid agonist effects
measure: Dose choice
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Treatment Research Center
state: Vermont
Study officials:
affiliation: University of Vermont
name: Warren Bickel, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07025616: Effects of Buteyko Breathing Exercise in Children With Uncontrolled Asthma
Official title: Effectiveness of Buteyko Breathing Exercise in Children With Uncontrolled Asthma: A Single Blind, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Breathing Techniques
Asthma Control Level
Asthma in Children
Asthma Patients
Breathing Exercise
Keywords: Asthma
Buteyko
breathing retraining
pediatrics
Lead sponsor: Indonesia University
Sponsor class: OTHER
Collaborators: name: Fakultas Kedokteran Universitas Indonesia
name: Dr Cipto Mangunkusumo General Hospital
First posted: 2025-06-17
Enrollment: 74
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized controlled trial study aimed to measure the effectiveness of the combination of 4-weeks Buteyko breathing exercises and pharmacological therapy compared with pharmacological therapy alone in children with uncontrolled asthma.


Eligibility criteria: Inclusion Criteria:

1. Children aged 7-17 years
2. Uncontrolled or partially controlled asthma (GINA Symptom Control Tool score \> 1)
3. Receive bronchodilator therapy, either oral or inhaler from a pediatrician.
4. Children and parents/care givers agree to participate in the study until the end, and parents/care givers sign the informed consent form.
5. Can understand instructions.

Exclusion Criteria:

1. Inpatients
2. Have received Buteyko breathing exercises or other breathing exercises.
3. Have congenital heart disease, pneumonia, or other significant and uncontrolled health disorders.
4. Have severe physical disabilities or mental retardation that could potentially prevent the implementation of Buteyko breathing exercises.
5. Have contraindications for spirometry examination

Primary outcomes:
measure: Asthma control
timeFrame: At enrollment and end of fourth-week
Secondary outcomes:
measure: Asthma Quality of Life
timeFrame: At enrollment and end of fourth-week
measure: Bronchodilator use
timeFrame: At end of fourth-week
measure: FEV1
timeFrame: At enrollment and end of fourth-week
measure: FVC
timeFrame: At enrollment and end of fourth-week
measure: FEV1/FVC
timeFrame: At enrollment and end of fourth-week
measure: PEFR
timeFrame: At enrollment and end of fourth-week
measure: Control Pause
timeFrame: At enrollment and end of fourth-week
Other outcomes:
Locations:
city: Jakarta Pusat
country: Indonesia
facility: Universitas Indonesia, Faculty of Medicine
state: Dki Jakarta
Study officials:
References:
Clinical trial NCT01564316: Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients
Official title: Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Biomarker With Neurodegeneration Patients
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2012-03-27
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: neurodegeneration patients group include dementia patients visited the part of neurology.

(almost after diagnosis)

Brief summary: Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Detailed description: Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Eligibility criteria: Inclusion Criteria:

* neurodegeneration patients and control group include dementia patients visited the part of neurology.
* over the age of 18
* when participants can understand subject of this study
* Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points.

exclusion criteria:

* under eighteen years of age
* when participants cannot understand subject of this study
* cannot accept this study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Neurology, Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Manho Kim, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT06172816: A Cohort Study on the Clinical Characteristics and Prognosis of HIV/AIDS Patients Infected With SARS-CoV-2
Official title: The Second Affiliated Hospital of Chongqing Medical University
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: PLWH
Covid-19
Clinical Features
Prognosis
Lead sponsor: The Second Affiliated Hospital of Chongqing Medical University
Sponsor class: OTHER
First posted: 2023-12-15
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy people and people living with HIV which is immunodeficient.

Brief summary: On February 11th, 2020, the International Classification of Viruses named the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as novel coronavirus (COVID-19, Covid-19 for short). At present, COVID-19 has become a global pandemic. However, the persistent replication of HIV in PLWH and the cellular immunodeficiency and persistent inflammation caused by it may have different effects on the susceptibility, severity and course of Covid-19. Several large cohort studies have found evidence of increased risk of hospitalization and death in patients with HIV and Covid-19 co-infection. Meanwhile, a meta-analysis of 22 studies shows that HIV infection is still an important risk factor for acquiring Covid-19 infection, and it is associated with a higher risk of death in COVID-19. In order to further clarify the clinical features and prognosis of HIV co-infection with Covid-19 and explore its immune mechanism, so we will carry out the study.


Eligibility criteria: Inclusion Criteria:

* Age 18-75 years old; Patients diagnosed with HIV in accordance with the Chinese AIDS Diagnosis and Treatment Guidelines.

Exclusion Criteria:

* Hypertension, diabetes and other metabolic related diseases; Severe circulatory and respiratory diseases; Patients with immune-related diseases and immunosuppressants; Pregnant and lactating women.

Primary outcomes:
measure: clinical features and prognosis
timeFrame: 2022.11-2023.1
measure: antibody titer
timeFrame: 2022.11-2023.1
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The second affiliated hospital of Chongqing medical university
state: Chongqing
Study officials:
References:
Clinical trial NCT05983016: Automatic Abdominal Aortic Aneurysm Diameter Measurement
Official title: Automated Three-dimensional Ultrasound Bridges the Gap Between Novices and Experts in Diameter Assessment of Abdominal Aortic Aneurysms
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: AAA - Abdominal Aortic Aneurysm
Keywords: Ultrasound
Three dimensional ultrasound
Abdominal aortic aneurysm
Sonography
3D ultrasound
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Philips Healthcare
First posted: 2023-08-09
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The ten patients were selected from a large vascular surgery outpatient clinic.

Brief summary: Managing abdominal aortic aneurysms currently relies on diameter assessment with ultrasound. Diameter reproducibility with two-dimensional ultrasound is challenging, and requires experienced operators. A novel automatic three-dimensional ultrasound system has the potential to facilitate more precise diameter measurements than two-dimensional ultrasound. This study aimed to assess the variance of abdominal aortic aneurysm diameter measurements among ultrasound novices and experts by comparing two-dimensional ultrasound with the three-dimensional ultrasound system in a clinical setting.

Ten patients under abdominal aortic aneurysm surveillance were examined by 29 ultrasound-operators: 13 experts and 16 novices. The experts were sonographers and physicians highly experienced in abdominal aortic aneurysm ultrasound, and the novices were medical students and junior residents with sparse ultrasound experience.


Eligibility criteria: Inclusion Criteria:

-Patients with an abdominal aortic aneurysm \> 3 cm.

Primary outcomes:
measure: Abdominal aortic aneurysm measurement variance between novices and experts
timeFrame: One week
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Vascular Surgery, Rigshospitalet
Study officials:
References: